An FT investigation has found a thriving market for stem cell therapies in the US promising longer, healthier lives. Experts say such claims are dangerous
Related stories
German distiller Berentzen in talks to sell to Sazerac
Why Newmont Stock Just Popped
Brinker's 2026 Outlook: Capital Allocation Targets $400 Million in Share Repurchases
There Are Over 3,000 Stocks in the Nasdaq Composite. And None Stand Out More Than This Ultimate Growth Stock in September.
What to Watch: KCHP
Southwest (LUV) Finally Joins the Lounge Business it Long Rejected